ABSTRACT
There are currently no preventative options for recurrent aphthous stomatitis, and the only available treatments are palliative. This is partly due to a poor understanding of its etiopathogenesis. In this case-control study, we characterized the salivary proteome of patients with recurrent aphthous stomatitis in the presence and absence of lesions. Through mass spectrometry-based proteomics and bioinformatics tools, we identified that the presence of oral ulcers is associated with several specific biological processes, including the metabolic pathways of vitamin B9, B12, nitrogen, selenium, and the bacterium Neisseria meningitidis. These changes occurred only in the presence of clinically visible lesions, and there were no relevant differences between patients in anatomical regions unaffected by ulcers. Additionally, using western blot and ELISA assays, we verified that carbonic anhydrase 1 (CA1, UniProtKB - P00915, CAH1_HUMAN) and hemoglobin subunit beta (HBB, UniProtKB - P68871, HBB_HUMAN) proteins are highly expressed during the ulcerative and remission phases of recurrent aphthous stomatitis. Our results cumulatively support saliva as an indicator of the pathophysiological changes, which occur during the clinical course of lesions. From a clinical perspective, we suggest that recurrent aphthous stomatitis is a condition triggered by temporary biological changes in people with lesions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the Chilean National Agency for Research and Development (ANID) PhD grant #2016-21161314 (to A.P.), ANID FONDECYT Regular num. #1180084 (to F.M.N. and L.S.S.), ANID FONDECYT Iniciacion num. #11180170 (to C.R.) and Concurso de Proyectos de Investigacion de Alto Nivel en Odontologia, Red Estatal de Odontologia num. #REO19-012 (to C.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were performed in accordance with the Declaration of Helsinki. The Ethics Committee of the University of Antofagasta (protocol #156/2018) approved this research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All supplementary files are included in this article and are publicly available at: https://doi.org/10.5281/zenodo.4482898. The mass spectrometry proteomic data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository 87 with the dataset identifier PXD026401 (https://www.ebi.ac.uk/pride/archive/projects/PXD026401). All other data supporting the findings of this study are available from the corresponding author on reasonable request.
